Discussion | This pilot study successfully explored the effect size of timolol eyedrops on migraine headaches. Several participants responded extremely well to the timolol. Further research is needed to determine what patient factors might predict responsiveness to timolol.
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An Autopsy Case of Progressive Supranuclear Palsy With Incidental ATXN2 Expansion
A case of multiple system atrophy with predominant parkinsonism (MSA-P) with ATXN2 (OMIM 601517) expansion was previously reported.
1 However, the autopsy in that patient showed tauopathy without evidence of spinocerebellar ataxia type 2 (SCA2). Herein, we present the pathologic findings to correct the previous misdiagnosis. This patient is case 3 in the previous report, 1 which details clinical history and examination. He died when he was in his late 60s due to pneumonia, 9 years after onset of the disease. A rare chance to examine MSA-P with low-range ATXN2 expansion prompted us to perform an autopsy.
Methods | General autopsy was carried out with routine procedure. The time from death to the postmortem examination was 17 hours. The half brain was stored in a deep freezer (−80°C) and the remaining half brain was fixed in 10% neutral formalin for 4 weeks. After fixation, formalin-fixed paraffin embedded blocks were cut as 5-μm thickness. Hematoxylin-eosin, glial fibrillary acidic protein (1:200 dilution; Dako), phosphorylated tau (1:300 dilution AT8; ThermoFisher), 3 repeat tau (1: 40 000 dilution; Merck), 4 repeat tau (1:10 000 dilution; Millipore), α-synuclein (phospho S129, 1: 200 dilution; Abcam), phosphorylated TDP43 (1:10 000 dilution; Cosmo Bio), phosphorylated neurofilaments (1: 10 000 dilution; Milipore), NeuN (1:500 dilution; Milipore), and 1C2 (1:200 dilution; Milipore) immunohistochemistry and Luxol fast blue staining were carried out. Permission for autopsy was granted by the family, and the study was approved by the institutional review board of the Seoul National University Hospital.
Results | The weight of the fresh brain was 1450 g. Gross autopsy findings showed mild cortical atrophy with sulcus widening. Prominent pontine atrophy with cerebellar involvement was seen. The globus pallidus was atrophic. The putamen, caudate nucleus, and hippocampus were preserved. Depigmentation was observed in the substantia nigra and locus coeruleus. Microscopic examination showed widespread neuronal loss with reactive gliosis in the globus pallidus, subthalamic nucleus, substantia nigra, colliculi, periaqueductal gray matter, and the dentate nucleus of the cerebellum. Numerous tau-positive, ubiquitin-negative globose tangles, and tufted astrocytes were seen in the brainstem, thalamus, basal ganglia, hippocampus, cortex, cerebellum, and cervical spinal cord ( Figure) . There was no Lewy body, neurite, or senile plaque pathology. No positive reaction, except for a few areas of weak granular staining in neuronal soma, was observed in 1C2 (antibody specific for polyglutamine) immunostaining.
Discussion | In the previous report, 1 possible MSA-P was diagnosed based on rapidly progressive parkinsonism, poor response to levodopa, recurrent falling, erectile dysfunction, and hyperreflexia. In retrospect, this patient showed clinical characteristics of progressive supranuclear palsy. Mild limitation of downward eye movement was suspected. He showed no prominent ataxia and urinary dysfunction, which was not sufficient for MSA criteria. There was a cognitive bias of anchoring toward parkinsonism with cerebellar ataxia that is MSA because of ATXN2 expansion. We thought that mild cerebellar atrophy was suggestive of MSA, but mild cerebellar atrophy may be found in progressive supranuclear palsy. 2 We conclude that our patient had progressive supranuclear palsy, and ATXN2 expansion is incidental. Pathologic changes in this case involved dentate nucleus, which is commonly spared in most patients with SCA2. 3 Moreover, the rarity of polyglutamine staining in this patient suggested that SCA2 did not contribute to the pathologic effects. In addition, 2 of his children (even though they are only in their late 30s) with same expansion number of 32 are neurologically normal. Ross et al 4 observed a significant association of expanded ATXN2 repeats with progressive supranuclear palsy. They also reported that repeats of 32 were found in a control population. 4 Our case highlights that rigorous examination of clinical relevance is critical in the interpretation of genetic test results, as shown in a previous report. To the Editor Recently, Wu et al 1 reported the case of an adult patient with late-onset cobalamin C disease who received an incorrect diagnosis of adult metachromatic leukodystrophy (MLD). In this patient, the disease onset was characterized by acute psychiatric symptoms and spastic paraparesis. A brain magnetic resonance imagining (MRI) scan performed 2 months after the onset showed an area of hyperintensity on fluidattenuated inversion recovery images in the right occipital subcortical white matter. The involvement of bilateral occipital white matter and centrum semiovale was evident at a follow-up MRI that was performed 21 months after the onset. At this time, arylsulfatase A (ARSA) enzyme activity was tested in peripheral blood leukocytes, and the results showed that the levels were half of the normal lower limit. Metachromatic leukodystrophy was suspected and the patient underwent genetic testing. This is an interesting case, but in our opinion, it is confounding to emphasize MLD in the differential diagnosis because it could have been ruled out much sooner. Acute psychiatric symptoms and spastic paresis of the lower limbs could be present at onset in adult MLD. However, in these cases, MRI demonstrates a typical initial involvement of the frontal periventricular white matter that extends to the corpus callosum and the more posterior white matter structures over time. 2 In the published images, the initial white matter alteration is in the occipital lobe. No clear periventricular white matter involvement is identified, and the tigroid patter that is typical for MLD is not present. To our knowledge, no case of adult MLD with initial occipital white matter alterations has ever been described. Further, in patients with MLD, the level of ARSA activity is usually less than 6% of normal activity 3 and, until recently, no case of a patient with MLD with an ARSA activity higher than 10% has ever been documented 4 (excluding very rare children with saposin-B deficiency). Notably, the level of ARSA activity that was described in this patient is typical for a carrier of a diseasecausing mutation or a pseudodeficiency allele. The possibility of a pseudodeficit in patients that present with ARSA activity reduction in the heterozygote range should always be considered, since a pseudodeficiency allele is present in up to 15% of the population. 5 For all the previously mentioned reasons, investigations for other causes of leukoencephalopathies should have been performed before gene testing for MLD to avoid delays of administering the correct diagnosis and therapy. These points should have been discussed to render the case more instructive for clinicians.
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